ArticleBMC oral health2025
ATP6V0A4 as a novel prognostic biomarker and potential therapeutic target in oral squamous cell carcinoma.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Investigating the Molecular Mechanisms of the Anticancer Effects of Eugenol and Cinnamaldehyde Against Colorectal Cancer (CRC) Cells In Vitro.International journal of molecular sciences · 2026Article
- The LAMB3-ITGA6 axis orchestrates epithelial repair in periodontitis via hemidesmosomal regulation and keratinization modulation.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIncreasing evidence indicates that the dysregulation of ATP6V0A4 is linked to aggressive behaviors in various types of cancer. Nevertheless, the exact role and molecular mechanisms of ATP6V0A4 in oral squamous cell carcinoma (OSCC) are not yet fully understood.
methodsThis study initially integrated TCGA and GEO databases for cross-platform differential gene screening. A prognostic model was constructed using univariate Cox regression and LASSO regression, complemented by random forest algorithms to identify core genes. Subsequently, a multi-omics analysis strategy was employed, systematically conducting pan-cancer expression profiling, human protein atlas validation, GO/KEGG enrichment analysis, clinicopathological feature correlation analysis, and tumor immune microenvironment assessment. Further, immunotherapy response prediction models and drug sensitivity analysis were utilized to define therapeutic potential. For experimental validation, RT-qPCR was performed to measure ATP6V0A4 expression in OSCC cell lines, and plasmid transfection technology was used to establish overexpression models, followed by systematic evaluation of its regulatory effects on tumor cell proliferation, migration, and invasion.
resultsOur findings reveal that low expression of ATP6V0A4 is significantly associated with poor prognosis in patients with OSCC. Moreover, the expression level of ATP6V0A4 shows a close correlation with clinical T staging. Further investigations demonstrate that the expression status of ATP6V0A4 is significantly associated with the distribution and function of follicular helper T cells, regulatory T cells, naive B cells, resting dendritic cells, and natural killer cells. Results from in vitro cell experiments indicate that overexpression of ATP6V0A4 can significantly suppress the proliferation, migration, and invasion capabilities of OSCC cells. Notably, OSCC patients with low ATP6V0A4 expression exhibit higher sensitivity to drugs such as GDC0810, GSK591, and MK8776. This discovery provides novel insights and potential strategies for the development of combination therapy regimens for OSCC.
conclusionsATP6V0A4 may serve as a novel prognostic biomarker and potential therapeutic target in oral squamous cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.